Loading…
Loading…
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.
Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma.
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan).
SYDNEY, June 12, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, and Adbri announce the delivery of MV Yampu, the world's first battery-powered self-unloading bulk carrier. The vessel was officially delivered at Jiangjiang Nanyang Shipyard on June 5, 2026, and has now departed on its maiden voyage to commence operations for Adbri in Birkenhead, South Australia.
Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons.